GSK's Bioelectronics R&D unit is pursuing a relatively new scientific field that could one day result in a new class of medicines that would not be pills or injections but miniaturised, implantable devices. 

Our vision for bioelectronic medicine
GSK believes that these devices could be programmed to read and correct the electrical signals that pass along the nerves of the body, including irregular or altered impulses that can occur in association with a broad range of diseases. The hope is that through these devices, disorders as diverse as inflammatory bowel disease, arthritis, asthma, hypertension and diabetes could be treated.

In 2013, we outlined our vision for bioelectronic medicines in this commentary piece in Nature journal.

Working towards the development of bioelectronic medicines

Introducing Galvani Bioelectronics

Kris Famm, VP of Bioelectronics R&D, GSK, explains what bioelectronic medicines are all about

Dr. Moncef Slaoui, bioelectronics pioneer talks about our innovative work on bioelectronic medicine